Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kulbir Rangi

Pain Medicine Philadelphia, PA Doctor of Osteopathy

NPI 1588309876 CMS profile 11336220

1420 Walnut St Ste 406, Philadelphia, PA 19102

Open in the dashboard

General payments

$1,585

16 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kulbir Rangi of Philadelphia, PA is reported in the CMS Open Payments database as having received $1,585 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $581 5
2024 General $680 7
2023 General $83 1
2022 General $241 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kulbir Rangi
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kulbir Rangi were reported at $581. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Kulbir Rangi Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $241 $335 $103–$1,149 $149
2023 $83 $376 $114–$1,228 $160
2024 $680 $387 $115–$1,173 $164
2025 $581 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $242 2 payments
  2. Amgen Inc. $206 2 payments
  3. Fidia Pharma USA Inc. $181 2 payments
  4. BioCryst US Sales Co., LLC $127 1 payment
  5. Lilly USA, LLC $122 1 payment
  6. Phathom Pharmaceuticals, Inc. $122 1 payment
  7. Janssen Biotech, Inc. $121 1 payment
  8. Teva Pharmaceuticals USA, Inc. $119 2 payments
  9. Genzyme Corporation $98 1 payment
  10. SI-BONE, Inc. $97 1 payment
  11. Other $150 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,429 15 payments
  2. Education $157 1 payment
Products named General payments · program years 2022–2025
  1. HYMOVIS $157 1 payment
  2. RICHPLAT ORTHO PRP SYSTEM $157 1 payment
  3. Orladeyo $127 1 payment
  4. AIRSUPRA $125 1 payment
  5. Otezla $123 1 payment
  6. MOUNJARO $122 1 payment
  7. VOQUEZNA $122 1 payment
  8. TREMFYA $121 1 payment
  9. SIMPONI ARIA $121 1 payment
  10. FARXIGA $117 1 payment
  11. Other $391 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

119

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$1,849

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

25.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clozapine Generic 13 $939
Venlafaxine Hcl Generic 12 $237
Bupropion Xl Bupropion Hcl Brand 14 $216
Clonazepam Generic 28 $165
Escitalopram Oxalate Generic 11 $125
Ziprasidone Hcl Generic 12 $119
Zolpidem Tartrate Generic 13 $28
Citalopram Hbr Citalopram Hydrobromide Brand 16 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
  • BioCryst US Sales Co., LLC $127
$127 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $122
$122 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $117
$117 — —
KEVZARA
  • GENZYME CORPORATION $98
$98 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record